Epratuzumab
drugOn this page
Also known as IMMU-HLL2
Summary
Epratuzumab (CHEMBL2108404) is a phase-3 clinical-stage antibody; indicated across 10 conditions including acute lymphoblastic leukemia and lymphoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 10 conditions
- Clinical trials: 27
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108404 |
| Name | Epratuzumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Epratuzumab, IMMU-HLL2, EPRATUZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| acute lymphoblastic leukemia | 3 | MONDO:0004967 | EFO:0000220 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| systemic lupus erythematosus | 3 | MONDO:0007915 | MONDO:0007915 |
| B-cell acute lymphoblastic leukemia | 2 | MONDO:0004947 | EFO:0000094 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| Waldenstrom macroglobulinemia | 2 | MONDO:0100280 | EFO:0009441 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| diffuse large B-cell lymphoma | 1 | MONDO:0018905 | EFO:0000403 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 27.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 13 |
| PHASE3 | 8 |
| PHASE1/PHASE2 | 5 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00022685 | PHASE3 | UNKNOWN | Epratuzumab in Treating Patients With Non-Hodgkin’s Lymphoma |
| NCT00111306 | PHASE3 | TERMINATED | Study of Epratuzumab in Systemic Lupus Erythematosus |
| NCT00382837 | PHASE3 | WITHDRAWN | Study of Epratuzumab in Systemic Lupus Erythematosus |
| NCT00383214 | PHASE3 | TERMINATED | Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) |
| NCT01261793 | PHASE3 | COMPLETED | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) |
| NCT01262365 | PHASE3 | COMPLETED | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus |
| NCT01408576 | PHASE3 | COMPLETED | Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus |
| NCT01802814 | PHASE3 | COMPLETED | International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 |
| NCT00042913 | PHASE2 | UNKNOWN | Epratuzumab in Treating Patients With Non-Hodgkin’s Lymphoma |
| NCT00044902 | PHASE2 | COMPLETED | Monoclonal Antibody Treatment for Non-Hodgkin’s Lymphoma (Low-Grade) |
| NCT00061425 | PHASE1/PHASE2 | COMPLETED | Treatment of Non-Hodgkin’s Lymphoma With 90Y-hLL2 IgG |
| NCT00098839 | PHASE1/PHASE2 | COMPLETED | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) |
| NCT00113802 | PHASE2 | TERMINATED | Study of Epratuzumab (hLL2) in Patients With Waldenstrom’s Macroglobulinemia |
| NCT00113971 | PHASE2 | TERMINATED | Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) |
| NCT00301821 | PHASE2 | COMPLETED | Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma |
| NCT00383513 | PHASE2 | COMPLETED | Study of Epratuzumab in Systemic Lupus Erythematosus |
| NCT00553501 | PHASE2 | COMPLETED | Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma |
| NCT00624351 | PHASE2 | COMPLETED | Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease |
| NCT00660881 | PHASE2 | COMPLETED | Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease |
| NCT00941928 | PHASE2 | TERMINATED | Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) |
| NCT00945815 | PHASE2 | COMPLETED | S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
| NCT01219816 | PHASE2 | COMPLETED | Multi-centric Study |
| NCT01279707 | PHASE1/PHASE2 | UNKNOWN | Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) |
| NCT01354457 | PHASE1/PHASE2 | UNKNOWN | Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ |
| NCT01449071 | PHASE1/PHASE2 | COMPLETED | Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) |
| NCT01534403 | PHASE2 | COMPLETED | Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects |
| NCT00398372 | Not specified | COMPLETED | Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma Patients Receiving Antibody Treatment |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).